Abstract:Synthetic short interfering RNA (siRNA) oligonucleotides can trigger the RNA interference pathway and lead to selective gene silencing. Despite considerable enthusiasm and investment, formidable challenges remain that may deter translating this breakthrough discovery into clinical applications. In particular, the development of efficient, nontoxic, nonimmunogenic methods for delivering siRNA in vivo has proven to be exceptionally challenging. Thorough analysis of the relationship between the structure and function of siRNA carrier systems, both in isolation and in complex with RNA, will facilitate the design of efficient nonviral siRNA delivery vehicles. In this study, we explore the relationship between the physicochemical characteristics and the biological activity of "lipitoid" compounds as potent siRNA delivery vehicles. Lipitoids are cationic peptidomimetic oligomers incorporating a peptoid and a phospholipid moiety. Lipitoids can associate with siRNA oligonucleotides and self-assemble into spherical lipitoid-based nanoparticles (LNPs), with dimensions that are dependent upon the medium and the stoichiometric ratio between the cationic monomers of the lipitoid and anionic siRNA oligonucleotides. The morphology, gene silencing efficiency, and cytotoxicity of the siRNA-loaded LNPs are similarly sensitive to the stoichiometry of the complexes. The medium in which the LNPs are formed affects the assembled cargo particles' characteristics such as particle size, transfection efficiency, and stability. Formation of the LNPs in the biological, serum-free medium OptiMEM resulted in LNPs an order of magnitude larger than LNPs formed in water, and were twice as efficient in siRNA transfection compared to LNPs formed in water. Inhibitor studies were conducted to elucidate the efficiency of lysosomal escape and the uptake mechanism of the siRNA-loaded LNPs. Our results suggest that these lipitoid-based, siRNA-loaded spherical LNPs are internalized through a lipid raft-dependent and dynamin-mediated pathway, circumventing endosomal and lysosomal encapsulation. The lipitoid-siRNA nanospheres proved to be suitable platforms for investigating the critical parameters determining the efficiency of transfection agents, revealing the necessity for conducting characterization studies in biological media. The investigation of the LNP internalization pathway points to an alternative uptake route that bypasses the lysosome, explaining the surprisingly high efficiency of LNPs and suggesting that the uptake mechanism should be probed rather than assumed for the next generation of rationally designed transfection agents.

The Effects of the Carrier and Ligand Spatial Conformation on RNA Nanodrug Cell Delivery

Spatiotemporal tracking of the transport of RNA nano-drugs: from transmembrane to intracellular delivery

Anisotropic active ligandations in siRNA-Loaded hybrid nanodiscs lead to distinct carcinostatic outcomes by regulating nano-bio interactions

Construction and Biological Evaluation of a Novel Integrin Ανβ3-Specific Carrier for Targeted Sirna Delivery in Vitro

Delivery Pathway Regulation of 3′,3″-Bis-peptide-sirna Conjugate Via Nanocarrier Architecture Engineering

Cell Type-Specific Delivery of RNAi by Ligand-Functionalized Curdlan Nanoparticles: Balancing the Receptor Mediation and the Charge Motivation

Research Progress of siRNA Drug Delivery Based on Self-Assembled Nanostructures of Nucleic Acids

Research progress on siRNA delivery with nonviral carriers.

Research Progress on Sirna Delivery with Nonviral Carriers

Noninvasive Imaging of C(Rgd)(2)-9r As A Potential Delivery Carrier for Transfection of Sirna in Malignant Tumors

Rigid Nanoparticle-Based Delivery of Anti-Cancer Sirna: Challenges and Opportunities.

Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery

Systemic and Tumor-Targeted Delivery of Sirna by Cyclic NGR and Isodgr Motif-Containing Peptides.

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Recent Advances in RNA-Targeted Cancer Therapy

Nano-based delivery of RNAi in cancer therapy

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity

Aptamer-functionalized silver nanoclusters-mediated cell type-specific siRNA delivery and tracking

Integrin Receptor-Mediated Strategy for Tumor Targeting Delivery of siRNA and Doxorubicin

Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA

Targeting Efficiency of RGD-modified Nanocarriers with Different Ligand Intervals in Response to Integrin Αvβ3 Clustering.